On September 14, Boston Scientific rose 3.3% in regular trading, trading at $44.14/share, with turnover of $118 million. The stock advanced alongside broad-based strength across the Health Care Equipment sector.

The rally came as the broader medical device sector saw widespread gains, with Stryker up 3.94%, Medtronic up 2.59%, Intuitive Surgical up 1.69%, and Abbott Laboratories up 1.37%. Boston Scientific has been recovering after a steep sell-off triggered by a cybersecurity incident first identified on August 25, which disrupted global operations and led the company to warn it is unlikely to meet its Q3 and full-year net sales growth and adjusted EPS guidance. Manufacturing has since resumed across most facilities globally, and the distribution network has been substantially restored.

Separately, Bernstein lowered its price target on Boston Scientific to $60 from $72 while maintaining an Outperform rating. The average analyst price target stands at $61.11, well above the current trading level, with a consensus Buy rating. The company is expected to provide its next official guidance update during the Q3 earnings call on October 28.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)